The management of heterozygous familial hypercholesterolaemia with high lipoprotein (a) and statin intolerance. The guidelines a mirage?

Abstract

Get full access to this article

View all access options for this article.

References

Veljić

Polovina

Milinković

, et al.

Lipoprotein apheresis and proprotein convertase subtilisin/kexin type 9 inhibitors: Do we have a vanquishing new strategy?

Eur J Prev Cardiol 2019; 26: 739–742.

Mach

Baigent

Catapano

, et al. ESC Scientific Document Group. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: Lipid modification to reduce cardiovascular risk. Eur Heart J. Epub ahead of print 31 August 2019. DOI: 10.1093/eurheartj/ehz455.

Sbrana F, Dal Pino B, Bigazzi F, et al. A large Italian cohort on PCSK9-inhibitors. Eur J Prev Cardiol. Epub ahead of print 25 November 2019. DOI: 10.1177/2047487319888059.

Kroon

van’t Hof

Demacker

, et al. The rebound of lipoproteins after LDL-apheresis. Kinetics and estimation of mean lipoprotein levels. Atherosclerosis 2000; 152: 519–526.

Bigazzi

Sbrana

Berretti

, et al. Reduced incidence of cardiovascular events in hyper-Lp(a) patients on lipoprotein apheresis. The G.I.L.A. (Gruppo Interdisciplinare Aferesi Lipoproteica) pilot study. Transfus Apher Sci 2018; 57: 661–664.

Leebmann

Roeseler

Julius

, et al. Pro(a)LiFe Study Group. Lipoprotein apheresis in patients with maximally tolerated lipid-lowering therapy, lipoprotein(a)-hyperlipoproteinemia, and progressive cardiovascular disease: prospective observational multicenter study. Circulation 2013; 128: 2567–2576.

Langsted

Nordestgaard

. Antisense oligonucleotides targeting lipoprotein(a). Curr Atheroscler Rep 2019; 21: 30–30.

Kim

Baek

. Lomitapide, relief pitcher for patients with homozygous familial hypercholesterolemia. Eur J Prev Cardiol. Epub ahead of print 11 October 2019. DOI: 10.1177/2047487319881240.

Lomitapide. Am J Cardiovasc Drugs 2011; 11: 347–352.

10.

Representatives of the Global Familial Hypercholesterolemia Community, Wilemon KA, Patel J, et al. Reducing the clinical and public health burden of familial hypercholesterolemia: A global call to action. JAMA Cardiol. Epub ahead of print 2 January 2020. DOI: 10.1001/jamacardio.2019.5173.